Site-Agnostic Cancer Drugs: HTAs Will Need Post-Approval Data

Early Scientific Advice From HTA Bodies Also Recommended

 
• By Neena Brizmohun
  
MoneyJar
Assessing value for money of cancer drugs is back in the spotlight • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Market Access